Craneware (LON:CRW) Shares Plunge 23% to Lowest Level Since 2016 After Cutting FY Revenue Outlook

Craneware plc shares fell as much as 23% today, touching an intraday low of 988 pence. That marks the stock’s lowest level since November 28, 2016. The Edinburgh-based healthcare financial software firm issued an unscheduled trading update warning that full-year results would miss market expectations. 

Craneware now guides FY26 revenue to $205 million to $208 million, with adjusted EBITDA of $65 million to $67 million. Both figures sit broadly flat versus last year, far short of the growth investors had priced in. The sell-off ranks among the sharpest single-day declines in the company’s trading history.

Why Craneware Stock Crashed Today

Craneware’s board flagged that trading in the final weeks of its financial year, which ended June 30, fell well short of plan. The company blamed slower-than-expected conversion of identified 340B opportunities into recognised revenue. That single disclosure wiped out nearly a quarter of the stock’s value in hours. The scale of the drop was specific to Craneware, not a broader AIM index move.

• FY26 revenue guidance: $205 million to $208 million
• Adjusted EBITDA guidance: $65 million to $67 million
• Both figures broadly in line with the prior year, not growth

What Went Wrong for Craneware

The 340B Drug Discount Timing Issue

Craneware pointed to pharmaceutical manufacturers’ restrictions on 340B-priced medicines as the root cause. These restrictions slowed the pace at which eligible drug activity converted into billable revenue. The company also deferred a small number of large enterprise contracts, which it now expects to close in FY27 instead. Management said the actual scale of the shortfall only became clear once real shipment volumes were confirmed late in the quarter.

Craneware #CRW
Share price 1,460p (pre-open)

FY26 revenue $205-208m, EBITDA $65-67m — dressed up as "in line with FY25" but H2 alone is DOWN yoy.

2nd guidance miss this fiscal year. 340B delays pushed to FY27, contracts deferred. Story broken?

A sharp reality check!
Exit4Now. pic.twitter.com/VjwLE0sblO

— Dearg Doom (@MyDeargDoom) July 3, 2026

Craneware’s Recent Financial Track Record

The miss stands in sharp contrast to Craneware’s first-half FY26 results. Revenue for H1 FY26 came in at $105.7 million, up 6% from $100.0 million a year earlier. Adjusted EBITDA rose 10% to $33.4 million, and annual recurring revenue reached $184.2 million, up 4% year over year. The board had also announced a $25 million share buyback program earlier this year, a move that signaled confidence now undercut by today’s warning.

• H1 FY26 revenue: $105.7 million, up 6% year over year
• H1 FY26 adjusted EBITDA: $33.4 million, up 10%
• Annual recurring revenue: $184.2 million, up 4%

Management’s Response to the Selloff

Craneware chief executive Keith Neilson called the miss disappointing given the growth the company had expected. He described the pharmacy market disruption as a short-term timing issue rather than a structural problem. Neilson pointed to rising customer demand for operational transformation work, not just software licensing, as evidence the underlying business remains intact. He also highlighted an expanding 340B Shelter opportunity as a reason for confidence heading into FY27.

Craneware Valuation and Related Stocks to Watch

Ahead of today’s update, Craneware traded on a price-to-earnings ratio near 14.57, with a market capitalisation close to £500 million. That valuation now sits well below where it stood before the warning. Investors tracking the healthcare revenue-cycle software space often watch Craneware alongside US-listed peer Health Catalyst, which serves a similar hospital analytics market. Other AIM-listed healthcare technology names may also see renewed scrutiny after today’s move, as investors reassess growth assumptions across the sector.

Final Thoughts

Craneware’s 23% plunge reflects a genuine earnings miss, not just a sentiment shift. The 340B timing issue and deferred contracts pushed real revenue into FY27, catching the market off guard. Strong H1 FY26 numbers and a recent buyback program show the underlying business was not broken heading into this update. Whether Craneware stock recovers will likely depend on how quickly those deferred enterprise contracts convert once the new financial year begins.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered  investment or trading advice